SCHEMBL343207

SCHEMBL343207

CCCCC(CC)C(=O)N(C)CC(C)(C)C=O

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.44
MAPK1 P28482 1/20 0.44
CA1 P00915 4/20 0.43
PDF Q9HBH1 4/20 0.38
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
USP2 O75604 1/20 0.33
CTSK P43235 1/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2058908 0.78 CA2 (0.55) CA2MAPK1CA1PDFSMN1; SMN2
SCHEMBL2058866 0.76 CA2 (0.53) CA2MAPK1CA1PDFSMN1; SMN2
SCHEMBL20450714 0.76 CA2 (0.48) CA2MAPK1CA1TSHR
SCHEMBL1882756 0.74 CA2 (0.59) CA2MAPK1CA1PDFSMN1; SMN2
SCHEMBL20450467 0.73 CA2 (0.50) CA2MAPK1CA1
SCHEMBL20450713 0.73 CA2 (0.50) CA2MAPK1CA1
SCHEMBL20450716 0.73 CA2 (0.50) CA2MAPK1CA1
SCHEMBL5970171 0.73 CA2 (0.55) CA2MAPK1CA1PDFSMN1; SMN2
SCHEMBL8055458 0.72 CA2 (0.57) CA2MAPK1CA1PDFSMN1; SMN2
SCHEMBL20450472 0.72 CA2 (0.45) CA2MAPK1CA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP claimed
US-9290603-B2 Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-03-22 US claimed
EP-2651875-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-09-12 US claimed
CN-103261145-A Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG 2013-08-21 CN claimed
WO-2012080264-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465842-A1 Amines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
US-8157950-B2 Aldimine and composition containing aldimine SIKA TECHNOLOGY AG (CH) 2012-04-17 US claimed
US-20110253309-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2011-10-20 US claimed
EP-2194082-B1 Aldimine and composition comprising aldimine SIKA TECHNOLOGY AG (CH) 2011-09-07 EP claimed
EP-2194082-A1 Aldimine and composition comprising aldimine Sika Technology AG (CH) 2010-06-09 EP claimed
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP disclosed
EP-2414418-B1 COMPOSITION CURABLE IN TWO STAGES COMPRISING A SURFACE DEACTIVATED POLYISOCYANATE SIKA TECH AG (CH) 2017-08-09 EP disclosed
US-9290603-B2 Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-03-22 US disclosed
US-9011630-B2 Hot curing or heat-activated composition containing a surface-deactivated polyisocyanate SIKA TECHNOLOGIES AG (CH) 2015-04-21 US disclosed
WO-2010112537-A1 COMPOSITION CONTAINING A SURFACE-DEACTIVATED POLYISOCYANATE AND CURING IN TWO STAGES SIKA TECHNOLOGY AG (CH) 2010-10-07 WO disclosed
EP-2236535-A1 Humidity curing polyurethane composition being accelerated by influence of heat Sika Technology AG (CH) 2010-10-06 EP disclosed
EP-2236533-A1 Heat curing or heat activatable composition comprising a surface deactivated polyisocyanate Sika Technology AG (CH) 2010-10-06 EP disclosed
EP-2236534-A1 Composition curable in two stages comprising a surface deactivated polyisocyanate Sika Technology AG (CH) 2010-10-06 EP disclosed
EP-2194082-A1 Aldimine and composition comprising aldimine Sika Technology AG (CH) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS AAAS, PNMT, PARG CA2 4635/4885MAPK1 3192/4885CA1 3359/4885
US-20110253309-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE ALDH7A1, ALDH3A1, ADH5 CA2 2967/4885MAPK1 3517/4885CA1 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.